Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia

American Journal of Hematology

Volumn 91, Issue 5, 2016, Pages 503-506

  Elala, Yoseph C ^a   Lasho, Terra L ^a   Gangat, Naseema ^a   Finke, Christy ^a   Barraco, Daniela ^a   Haider, Mahnur ^a   Abou Hussein, Ahmed K ^a   Hanson, Curtis A ^a   Ketterling, Rhett P ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; HEMOGLOBIN; JANUS KINASE 2; MPL PROTEIN; PROTEIN; UNCLASSIFIED DRUG; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ARTICLE; BLAST TRANSFORMATION; CANCER SURVIVAL; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICAL HISTORY; MORTALITY RATE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; OVERALL SURVIVAL; PHENOTYPE; POLYCYTHEMIA; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; COMPARATIVE STUDY; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MUTATION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CALRETICULIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, THROMBOPOIETIN; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 84962858012     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24338     Document Type: Article

References (24)

1. Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28:1407-1413.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. 2009;937-951.
3. Barbui T, Thiele J, Vannucchi AM, et al. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 2015;5:e337
4. Tefferi A, Barbui T. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. Mayo Clin Proc 2015; 90:1283-1293.
5. Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol 2016;91:50-58.
6. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507-2513; quiz 2615.
7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med 2013;369:2379-2390.
8. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544-1551.
9. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 2014;124:2465-2466.
10. Tefferi A, Pardanani A. Myeloproliferative neoplasms. A Contemporary Review. JAMA Oncol 2015;1:97-105.
11. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med 2013;369:2391-2405.
12. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-1555.
13. Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014;28:2300-2303.
14. Hultcrantz MKS, Andersson TM, Landgren O, et al. Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study. J Clin Oncol 2012;2995-3001.
15. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An International Study. J Clin Oncol 2011;29:3179-3184.
16. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors. Blood Cancer J 2015;5:e366.
17. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol 2014;89:E121-E124.
18. Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica 2015;100:893-897.
19. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2007;22:437-438.
20. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-1869.
21. Barbui T, Thiele J, Vannucchi AM, et al. Myeloproliferative neoplasms: Morphology and clinical practice. Am J Hematol, in press.
22. Haider M, Gangat N, Lasho T, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol, in press.
23. Tefferi A, Lasho TL, Finke C, et al. Targeted next-generation sequencing in polycythemia vera and essential thrombocythemia. Blood 2015;126:354-354.
24. Tefferi A, Lasho TL, Finke C, et al. A 27-gene NGS panel in primary myelofibrosis identifies ASXL1, CBL, RUNX1 and SRSF2 mutations as being unfavorable and absence of any non-driver mutation as being favorable to survival. Blood 2015;126:350-350.